PODD Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.…
Industry Peers
Medical DevicesKey Statistics
About Insulet (NASDAQ: PODD)
›
Insulet (NASDAQ: PODD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 5,400 employees.
The shares were at 137.23 USD on 19 November 2026, down 56.4% over 52 weeks. Its 52-week range is 126.50 USD to 354.88 USD: the price is 61.3% below the high and 8.5% above the low.
At a market capitalisation of 9.52B USD, it trades at 22.4 times trailing earnings and 17.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 12% for PODD.
Insulet reports return on equity of 16.3%, an operating margin of 18.4% and revenue up 19.2% year over year.
Its debt exceeds its cash by 454.00M USD, a debt-to-equity ratio of 0.63. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 177.91 USD is 29.6% above the current price. The next earnings report is expected on 17 February 2027.